Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

Delayed Quote. Delayed  - 07/26 10:02:04 pm
108.35 USD   +1.72%
07/26 EDWARDS LIFESCI : tops Street 2Q forecasts
07/26 EDWARDS LIFESCI : Reports Second Quarter Results
07/21EDWARDS LIFESCI : half-yearly earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CEST

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
07/26 EDWARDS LIFESCIENCES : tops Street 2Q forecasts
07/26 EDWARDS LIFESCIENCES CORP : Results of Operations and Financial Condition, Finan..
07/26 EDWARDS LIFESCIENCES : Reports Second Quarter Results
07/21EDWARDS LIFESCIENCES CORP : half-yearly earnings release
07/20 EDWARDS LIFESCIENCES : Assigned Patent
07/16 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Ju..
07/15 EDWARDS LIFESCIENCES : To Host Earnings Conference Call On July 26, 2016
07/14 EDWARDS LIFESCIENCES : Trademark Application for "DATASPHERE" Filed by Edwards L..
07/13 EDWARDS LIFESCIENCES : To Host Earnings Conference Call On July 26, 2016
07/11 MEDTRONIC : Global Plaque and Thrombus Management Devices Market 2016 - Abbott, ..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
07/25DJADRs End Lower; Philips Rises
07/25DJPHILIPS : Cost Savings, Strong Sales Boost Philips' Earnings
07/25DJPHILIPS : Profit Lifted by Health Technology Business
07/21 MCKESSON : Theranos hires executives in regulatory, compliance push
07/21DJTheranos Hires Compliance, Regulatory Executives
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
09:23a PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
09:21a Edwards Q2 top line up 23%; EPS up 14%; shares ahead 8% premarket
05:33a Edwards Lifesciences (EW) Michael A. Mussallem on Q2 2016 Results - Earnings ..
07/26 After Hours Gainers / Losers
07/26 Edwards Lifesciences beats by $0.06, beats on revenue
Advertisement
Financials ($)
Sales 2016 2 900 M
EBIT 2016 791 M
Net income 2016 592 M
Finance 2016 563 M
Yield 2016 -
P/E ratio 2016 39,87
P/E ratio 2017 33,27
EV / Sales 2016 7,72x
EV / Sales 2017 6,86x
Capitalization 22 944 M
More Financials
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Full-screen chart
Technical analysis trends EDWARDS LIFESCIEN...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 117 $
Spread / Average Target 7,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John P. McGrath Vice President-Quality, Regulatory & Clinical
John T. Cardis Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES C..37.19%22 944
THERMO FISHER SCIENTIF..12.01%62 525
BOSTON SCIENTIFIC CORP..30.04%32 538
INTUITIVE SURGICAL, IN..25.72%26 430
PHILIPS3.52%25 436
ILLUMINA, INC.-21.80%22 095
More Results